Sodium-glucose transporter inhibition in heart failure: from an unexpected side effect to a novel treatment possibility.
TLDR
Sodium-glucose transporter-2 inhibitors (SGLT2i) have been studied in large cardiovascular outcome trials to ascertain safety as discussed by the authors, and the results of these studies have been taken into account in recently issued guidelines for the management of diabetes and cardiovascular disease.About:
This article is published in Diabetes Research and Clinical Practice.The article was published on 2021-05-01 and is currently open access. It has received 10 citations till now. The article focuses on the topics: Type 2 diabetes & Diabetes mellitus.read more
Citations
More filters
Journal ArticleDOI
Impact of dapagliflozin treatment on renal function and diuretics use in acute heart failure: a pilot study
K. Charaya,Dmitry Shchekochikhin,Denis Andreev,I. E. Dyachuk,Svetlana V. Tarasenko,M. G. Poltavskaya,Dinara F. Mesitskaya,Alexandra A Bogdanova,N A Ananicheva,Alina Kuzub +9 more
TL;DR: The use of dapagliflozin was associated with a more pronounced weight loss and less need to increase diuretic therapy without significant deterioration of the renal function and did not improve the in-hospital and 30-day prognosis after discharge.
Journal ArticleDOI
The Design of Multi-target Drugs to Treat Cardiovascular Diseases: Two (or more) Birds on one Stone.
L Caruso,Nathalia Fonseca Nadur,Marina Brandão,Larissa de Almeida Peixoto Ferreira,Renata Barbosa Lacerda,Cedric Stephan Graebin,Arthur Eugen Kümmerle +6 more
TL;DR: This review aims to highlight the efforts and rational pharmacological bases for the design of some promising multitargeted compounds to treat important cardiovascular diseases like heart failure, atherosclerosis, acute myocardial infarction, pulmonary arterial hypertension and arrhythmia.
Journal ArticleDOI
Sodium-Glucose Cotransporter Inhibitors as Antidiabetic Drugs: Current Development and Future Perspectives
Rosanna Maccari,Rosaria Ottanà +1 more
TL;DR: The discovery that intestinal SGLT-1 inhibition can provide a novel opportunity to control hyperglycemia, through a multifactorial mechanism, recently encouraged the design of low adsorbable inhibitors selectively directed to the intestinal S gliflozins subtype, representing a compelling strategy to identify new antidiabetic drug candidates.
Journal ArticleDOI
Effects of GLP-1RA and SGLT2i, Alone or in Combination, on Mouse Models of Type 2 Diabetes Representing Different Disease Stages.
TL;DR: In this paper, the effects of single or combined use of liraglutide (a GLP-1RA) and ipragliflozin (a SGLT2i) for treating type 2 diabetes (T2DM) were evaluated.
Journal ArticleDOI
SGLT2 Inhibitors in Type 2 Diabetes Mellitus.
TL;DR: Sodium-glucose cotransporter 2 inhibitors were first discovered as glucose-lowering drugs because of their glycosuric action and good safety profile as discussed by the authors , which paved the way to a larger use of these drugs in patients with heart failure, with the aim of improving their clinical outcomes and quality of life.
References
More filters
Journal ArticleDOI
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman,Christoph Wanner,John M. Lachin,David Fitchett,Erich Bluhmki,Stefan Hantel,Michaela Mattheus,Theresa Devins,Odd Erik Johansen,Hans-Juergen Woerle,Uli C. Broedl,Silvio E. Inzucchi +11 more
TL;DR: Patients with type 2 diabetes at high risk for cardiovascular events who received empagliflozin, as compared with placebo, had a lower rate of the primary composite cardiovascular outcome and of death from any cause when the study drug was added to standard care.
Journal ArticleDOI
Canagliflozin and cardiovascular and renal events in type 2 diabetes
Bruce Neal,Vlado Perkovic,Vlado Perkovic,Kenneth W. Mahaffey,Dick de Zeeuw,Greg Fulcher,Ngozi Erondu,Wayne Shaw,Gordon Law,Mehul Desai,David R. Matthews +10 more
TL;DR: Patients treated with canagliflozin had a lower risk of cardiovascular events than those who received placebo but a greater risk of amputation, primarily at the level of the toe or metatarsal.
Journal ArticleDOI
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
John J.V. McMurray,Scott D. Solomon,Silvio E. Inzucchi,Lars Køber,Mikhail Kosiborod,Felipe Martinez,Piotr Ponikowski,Marc S. Sabatine,Marc S. Sabatine,Inder S. Anand,Jan Bělohlávek,Michael Böhm,Chern-En Chiang,Chern-En Chiang,Vijay K. Chopra,Rudolf A. de Boer,Akshay S. Desai,Mirta Diez,Jarosław Drożdż,Andrej Dukát,Junbo Ge,Jonathan G. Howlett,Jonathan G. Howlett,Tzvetana Katova,Masafumi Kitakaze,Charlotta Ljungman,Béla Merkely,Jose C. Nicolau,Eileen O'Meara,Mark C. Petrie,Pham Nguyen Vinh,Morten Schou,Tereshchenko Sn,Subodh Verma,Claes Held,David L. DeMets,Kieran F. Docherty,Pardeep S. Jhund,Olof Bengtsson,Mikaela Sjöstrand,AM Langkilde +40 more
TL;DR: Among patients with heart failure and a reduced ejection fraction, the risk of worsening heart failure or death from cardiovascular causes was lower among those who received dapagliflozin than amongThose who received placebo, regardless of the presence or absence of diabetes.
Journal ArticleDOI
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
TL;DR: The cardiovascular safety profile of dapagliflozin, a selective inhibitor of sodium–glucose cotransporter 2 that promotes glucosuria in patients with type 2 diabetes, is undefined.
Journal ArticleDOI
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Vlado Perkovic,Vlado Perkovic,Meg Jardine,Meg Jardine,Bruce Neal,Bruce Neal,Bruce Neal,Severine Bompoint,Hiddo J.L. Heerspink,David M. Charytan,David M. Charytan,Robert Edwards,Rajiv Agarwal,Rajiv Agarwal,George L. Bakris,Scott Bull,Christopher P. Cannon,Christopher P. Cannon,George Capuano,Pei-Ling Chu,Dick de Zeeuw,Tom Greene,Adeera Levin,Carol A. Pollock,David C. Wheeler,Yshai Yavin,Hong Zhang,Bernard Zinman,Gary Meininger,Barry M. Brenner,Kenneth W. Mahaffey +30 more
TL;DR: In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years.